<DOC>
	<DOCNO>NCT02453581</DOCNO>
	<brief_summary>A single centre , open , control study use Blood Stage Plasmodium falciparum challenge inoculum ( BSPC ) model ass effectiveness three dose level experimental anti-malarial product , OZ439 .</brief_summary>
	<brief_title>Effectiveness OZ439 Against Early Plasmodium Falciparum Blood Stage Infection Healthy Volunteers</brief_title>
	<detailed_description>This single center study use blood stage Plasmodium falciparum challenge inoculum characterize effectiveness OZ439 early blood stage Plasmodium Falciparum infection . The study conduct three cohort ( n=8 ) use different dos OZ439 . Dose escalation take place review observe OZ439 safety pharmacodynamic outcome previous cohort Safety Review Team . Single dose 100 mg , 200 mg 500 mg administer orally participant Cohort 1 , Cohort 2 Cohort 3 respectively .</detailed_description>
	<criteria>Volunteers adult ( male non pregnant female ) , age 18 45 year live alone ( Day 1 least end antimalarial drug treatment ) . Volunteers must BMI within range 1830 . Volunteers must understand procedure involve agree participate study give fully inform , write consent . Be contactable available duration trial ( maximum 4 week ) . Volunteers must nonsmoker good health , assess prestudy medical examination review screen result . Female participant childbearing potential , surgically sterile use insertable , injectable , transdermal , combination oral contraceptive approve US FDA Therapeutic Goods Administration ( TGA ) combine barrier contraceptive completion study negative result serum urine pregnancy test do administration study medication . Good peripheral venous access . History malaria . Travelled live ( 2 week ) malariaendemic country past 12 month plan travel malariaendemic country course study . Has evidence increase cardiovascular disease risk ( define great 10 % , 5 year risk ) History splenectomy . History severe allergic reaction , anaphylaxis convulsion follow vaccination infusion . Presence current suspect serious chronic disease cardiac autoimmune disease ( HIV immunodeficiency ) , insulin dependent diabetes , progressive neurological disease , severe malnutrition , acute progressive hepatic disease , acute progressive renal disease , psoriasis , rheumatoid arthritis , asthma , epilepsy obsessive compulsive disorder , skin carcinoma exclude nonspreadable skin cancer basal cell squamous cell carcinoma . Known inherit genetic anomaly ( know cytogenetic disorder ) e.g. , Down 's syndrome Volunteers unwilling defer blood donation Australian Red Cross Blood Service ( ARCBS ) 6 month . The volunteer diagnosis schizophrenia , severe depression , bipolar disease , severe ( disable ) chronic psychiatric diagnosis . Participants receive single antidepressant drug stable least 3 month prior enrollment without decompensating may allow enroll study investigator 's discretion . 10 ) Presence acute infectious disease fever ( e.g. , sublingual temperature 38.5 degree C ) within five day prior study product administration . Evidence acute illness within four week trial prior screen . Significant intercurrent disease type , particular liver , renal , cardiac , pulmonary , neurologic , rheumatologic , autoimmune disease history , physical examination , and/or laboratory study include urinalysis . Have ever receive blood transfusion . Evidence condition , opinion clinical investigator , might interfere evaluation study objective pose excessive risk participant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>